Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Cartesian Therapeutics

03/08/2026 13:42

Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026
The Frederick Maryland-based  company is expected to report a 54.8% decrease in revenue to $134.75 thousand from $298 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Cartesian Therapeutics Inc is for a loss of 87 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $39.00, about 400% above its last closing price of $7.80
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.91
-0.88
-1.46
Missed
-65.3
Dec. 31 2026
-0.86
-0.85
-3.57
Missed
-318.3
Sep. 30 2025
-0.81
-0.84
-1.38
Missed
-63.3​
Jun. 30 2025
-0.81
-0.81
0.50
Beat
161.7
​​Mar. 31 2025
-0.71
-0.71
-0.68
Beat
3.6
Dec. 31 2024
-0.87
-0.80
-0.59
Beat
26.3​
Sep. 30 2024
-0.78
-0.91
-1.13
Missed
-24.2
Jun. 30 2024
-0.91
-1.13
0.54
Beat
147.8
This summary was machine generated August 3 at 12:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)